Risk of Certain Adverse Outcomes Up With Endoscopy in Pregnancy

Share this content:
Risk of Certain Adverse Outcomes Up With Endoscopy in Pregnancy
Risk of Certain Adverse Outcomes Up With Endoscopy in Pregnancy

TUESDAY, Feb. 7, 2017 (HealthDay News) -- Endoscopy during pregnancy is associated with increased risk of preterm birth or small for gestational age, according to a study published in the February issue of Gastroenterology.

Jonas F. Ludvigsson, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a nationwide population-based cohort study linking data from the Swedish Medical Birth Registry and the Swedish Patient Registry. A total of 3,052 pregnancies exposed to endoscopy were identified (2,025 upper endoscopies, 1,109 lower endoscopies, and 58 endoscopic retrograde cholangiopancreatographies); pregnancy outcomes were compared with 1,589,173 unexposed pregnancies.

The researchers observed a significantly increased risk of preterm birth (adjusted relative risk [ARR], 1.54; 95 percent confidence interval [CI], 1.36 to 1.75) or small for gestational age (ARR, 1.3; 95 percent CI, 1.07 to 1.57) with exposure to any endoscopy, but no significantly increased risk of congenital malformation (ARR, 1; 95 percent CI, 0.83 to 1.2) or stillbirth (ARR, 1.45; 95 percent CI, 0.87 to 2.4). For women with endoscopy, none of the stillbirths occurred less than two weeks after endoscopy. The ARRs were not dependent on trimester.

"In a nationwide population-based cohort study, we found endoscopy during pregnancy to be associated with increased risk of preterm birth or small for gestational age, but not of congenital malformation or stillbirth," the authors write. "However, these risks are small and likely due to intrafamilial factors or disease activity."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »